{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:05:08Z","timestamp":1784613908232,"version":"3.55.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>ALK<\/jats:italic>\n                      rearrangements are rare in gastric cancer, and their therapeutic relevance remains poorly defined. While ALK inhibitors have demonstrated efficacy in lung cancer and other malignancies, data in gastric tumors are limited.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      We report a 52-year-old woman with metastatic gastric adenocarcinoma harboring a rare\n                      <jats:italic>SPTBN1<\/jats:italic>\n                      \u2013\n                      <jats:italic>ALK<\/jats:italic>\n                      fusion detected at a low variant allele frequency (0.65%). The tumor was negative for HER2 amplification, microsatellite instability, and PD-L1 expression. After failure of chemotherapy combined with immunotherapy, treatment with the ALK inhibitor iruplinalkib resulted in rapid clinical improvement and a durable partial response lasting approximately 14 months. Serial next-generation sequencing at progression demonstrated enrichment of the fusion-positive clone (variant allele frequency increased to 5.94%), accompanied by expansion of TP53-mutant alleles and acquisition of additional genomic alterations. Subsequent histologic transformation to small-cell neuroendocrine carcinoma was observed, with loss of RB expression and markedly elevated Ki-67. No canonical ALK kinase domain resistance mutations were detected, suggesting a non\u2013on-target resistance mechanism.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case highlights that even low-allele-frequency ALK fusions may have important clinical relevance in gastric cancer and may identify patients who could benefit from ALK-targeted therapy. It also illustrates the dynamic evolutionary trajectory of oncogene-driven tumors under therapeutic pressure, with histologic transformation to small-cell neuroendocrine carcinoma that may reflect lineage plasticity. Comprehensive genomic profiling and longitudinal molecular monitoring may facilitate the identification of rare actionable alterations and improve understanding of resistance mechanisms in advanced gastric cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1832676","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:35:36Z","timestamp":1784612136000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Durable response to ALK inhibition in low-allele-frequency SPTBN1\u2013ALK\u2013rearranged gastric cancer followed by lineage plasticity\u2013mediated resistance: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Zihua","family":"Guan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Changshan County People\u2019s Hospital","place":["Quzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Changshan County People\u2019s Hospital","place":["Quzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlu","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Changshan County People\u2019s Hospital","place":["Quzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Changshan County People\u2019s Hospital","place":["Quzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Changshan County People\u2019s Hospital","place":["Quzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00052-2","article-title":"Gastric cancer","volume":"405","author":"Sundar","year":"2025","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03785-6","article-title":"AI-based large-scale screening of gastric cancer from noncontrast CT imaging","volume":"31","author":"Hu","year":"2025","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2025.05.007","article-title":"Gastric cancer: from biomarkers to functional precision medicine","volume":"31","author":"Albrecht","year":"2025","journal-title":"Trends Mol Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41698-023-00449-x","article-title":"ALK fusions in the pan-cancer setting: another tumor-agnostic target","volume":"7","author":"Shreenivas","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1686666","article-title":"Response to anaplastic lymphoma kinase inhibitor in gastric cancer harboring DCTN1-ALK fusion: a case report and review","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0439","article-title":"Carcinoma of unknown primary with EML4-ALK fusion response to ALK inhibitors","volume":"24","author":"Zhao","year":"2019","journal-title":"Oncologist"},{"key":"B9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharmacol Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.3390\/ijms19113448","article-title":"Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase: A catalytic receptor with many faces","volume":"19","author":"Huang","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2015.1095407","article-title":"Anaplastic lymphoma kinase: Role in cancer and therapy perspective","volume":"16","author":"Zhao","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00419","article-title":"Monomerization of ALK fusion proteins as a therapeutic strategy in ALK-rearranged non-small cell lung cancers","volume":"10","author":"Hirai","year":"2020","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: A randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00797-9","article-title":"ALK in cancer: from function to therapeutic targeting","volume":"25","author":"Voena","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2673","article-title":"Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies","volume":"18","author":"Lipson","year":"2012","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/po.22.00015","article-title":"ALK inhibitors in patients with ALK fusion-positive GI cancers: an international data set and a molecular case series","volume":"6","author":"Ambrosini","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3233\/cbm-160599","article-title":"Anaplastic lymphoma kinase (ALK) gene alteration in gastric signet ring cell carcinoma","volume":"16","author":"Zhao","year":"2016","journal-title":"Cancer biomark"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.645370","article-title":"Case report: RAB10-ALK: A novel ALK fusion in a patient with gastric cancer","volume":"11","author":"Wen","year":"2021","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-17-1256","article-title":"Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer","volume":"8","author":"Yoda","year":"2018","journal-title":"Cancer Discov"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.Mcr-18-0171","article-title":"ALK fusion partners impact response to ALK inhibition: differential effects on sensitivity, cellular phenotypes, and biochemical properties","volume":"16","author":"Childress","year":"2018","journal-title":"Mol Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00886-z","article-title":"Pathogenic SPTBN1 variants cause an autosomal dominant neurodevelopmental syndrome","volume":"53","author":"Cousin","year":"2021","journal-title":"Nat Genet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12885-023-10789-3","article-title":"Clinical significance of nonerythrocytic spectrin Beta 1 (SPTBN1) in human kidney renal clear cell carcinoma and uveal melanoma: a study based on Pan-Cancer Analysis","volume":"23","author":"Tang","year":"2023","journal-title":"BMC Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13039-018-0405-1","article-title":"Rare gene fusion rearrangement SPTNB1-PDGFRB in an atypical myeloproliferative neoplasm","volume":"11","author":"Furtado","year":"2018","journal-title":"Mol Cytogenet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jcp.28975","article-title":"SPTBN1 and cancer, which links","volume":"235","author":"Chen","year":"2020","journal-title":"J Cell Physiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-016-0296-8","article-title":"Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy","volume":"9","author":"Gu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.07.002","article-title":"A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy","volume":"35","author":"Grand","year":"2007","journal-title":"Exp Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000001512","article-title":"Colorectal adenocarcinomas harboring ALK fusion genes: A clinicopathologic and molecular genetic study of 12 cases and review of the literature","volume":"44","author":"Lasota","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144731","article-title":"Anaplastic lymphoma kinase rearrangement in digestive tract cancer: implication for targeted therapy in chinese population","volume":"10","author":"Ying","year":"2015","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41467-017-01470-y","article-title":"Prevalence and detection of low-allele-fraction variants in clinical cancer samples","volume":"8","author":"Shin","year":"2017","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106822","article-title":"Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation Duplex Sequencing","volume":"115","author":"Kamath-Loeb","year":"2022","journal-title":"Leuk Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1308313","article-title":"Clinical and molecular profiling of EGFR-mutant lung adenocarcinomas transformation to small cell lung cancer during TKI treatment","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0340-z","article-title":"Lineage plasticity in cancer: a shared pathway of therapeutic resistance","volume":"17","author":"Quintanal-Villalonga","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1006480","article-title":"Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers","volume":"13","author":"Li","year":"2022","journal-title":"Front Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09985-x","article-title":"Critical role for a high-plasticity cell state in lung cancer","volume":"651","author":"Chan","year":"2026","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn0478","article-title":"Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling","volume":"377","author":"Chan","year":"2022","journal-title":"Sci (New York NY)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00475-x","article-title":"A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets","volume":"3","author":"Wang","year":"2022","journal-title":"Nat Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3390\/ijms27010445","article-title":"Lineage plasticity and histologic transformation in EGFR-TKI resistant lung cancer","volume":"27","author":"Lau","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1191311","article-title":"Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution","volume":"14","author":"Imamura","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"oyae020","DOI":"10.1093\/oncolo\/oyae020","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors show activity in colorectal cancer with ALK rearrangements: case series and literature review","volume":"30","author":"Hu","year":"2025","journal-title":"Oncologist"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/po.20.00383","article-title":"Impact of ALK inhibitors in patients with ALK-rearranged nonlung solid tumors","volume":"5","author":"Takeyasu","year":"2021","journal-title":"JCO Precis Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1832676\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:35:37Z","timestamp":1784612137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1832676\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":42,"alternative-id":["10.3389\/fonc.2026.1832676"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1832676","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1832676"}}